Skip to content

Acute pain control with morphine suppository

Analgesic effects of morphine suppository versus intravenous morphine in patients with extremity bone fracture: A placebo-controlled double-blind randomized clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201505218104N12
Enrollment
224
Registered
2017-08-20
Start date
2017-09-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain in extrimity fracture. Injury, poisoning and certain other consequences of external causes

Interventions

Intervention 1: Control group will receive intravenous morphine 5 mg and placebo suppository . Intervention 2: Case group will receive 10 mg suppository morphine and 5 ml of intravenous distilled wate
Treatment - Drugs
Control group will receive intravenous morphine 5 mg and placebo suppository .
Case group will receive 10 mg suppository morphine and 5 ml of intravenous distilled water.

Sponsors

Vice Chancellor of Research of Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: trauma patients with acute extremity fracture between 18 and 70 years old who have moderate to severe pain according to their visual analogue scale (VAS) score (score equal or higher than 5 of 10) Exclusion Criteria: known opioid allergy, a history of current/past drug abuse, other concurrent causes of pain (including trauma to other site), history of any chronic diseases (like respiratory, renal, hepatic, or heart failure), any conditions impairing the patient’s cooperation and participation in study (including altered consciousness, mental disorders and language barrier), pregnant and breastfeeding women and patients who had received analgesics 24 hours before admission

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Severity of pain. Timepoint: 0.30.60 minutes and 1,3,6,12,18,24 hour. Method of measurement: numerical criteria on the base of VAS score.

Secondary

MeasureTime frame
Apnea,decreased Oxygen suturation, decreased level of consciousness, decreased blood pressure, nausea and vomiting. Timepoint: 0-30-60 minutes and 1,3,6,12,18,24 hour. Method of measurement: Checking the patients respiratory rate, Oxygen saturation on pulse oximetry, checking blood pressure and asking about nausea and vomiting.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHoda Taghipour

Iran University of Medical Sciences

negareirani1983@yahoo.com+98 21 8805 2963

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026